A nurse is caring for a client who is receiving furosemide IV every 6 hr. Which of the following new prescriptions should the nurse recognize as a potential interaction?

Lithium is a mood stabilizer commonly used in the management of bipolar disorder, particularly for the treatment and prevention of manic episodes. It has a narrow therapeutic index, meaning that the difference between therapeutic and toxic levels is small. Lithium is excreted primarily through the kidneys, and factors that affect renal function, sodium balance, or fluid status can significantly increase the risk of toxicity. Neurological manifestations are among the earliest and most serious indicators of lithium toxicity and require immediate intervention.

Rationale:
A.Drowsiness is an early and relatively mild manifestation of lithium accumulation and may occur when serum levels begin to rise above the therapeutic range. While it should be monitored closely, it is not the most critical or immediately life-threatening finding. It can be associated with mild toxicity or dose adjustment needs, but does not independently indicate severe toxicity requiring emergency intervention.

B.Seizure is a severe and life-threatening manifestation of lithium toxicity and indicates significant central nervous system involvement. As lithium levels rise, neuronal excitability becomes increasingly impaired, leading to tremors, confusion, ataxia, and eventually seizures or coma. The occurrence of seizures requires immediate discontinuation of lithium, urgent medical intervention, and possible emergency treatment such as airway support and hemodialysis.

C.Weight gain is a common long-term side effect of lithium therapy due to metabolic changes and fluid retention. While it may be distressing for the client and require counseling on diet and lifestyle, it is not an acute sign of toxicity. It does not require immediate provider notification unless associated with other concerning symptoms.

D.Muscle weakness can occur with lithium therapy and may be related to electrolyte imbalances or mild neuromuscular effects. However, it is not a definitive indicator of severe toxicity on its own. It should be assessed in conjunction with other symptoms such as tremors, confusion, or gastrointestinal distress to determine clinical significance.

Anaphylaxis is a severe type I hypersensitivityreaction characterized by systemic mast cell degranulation and bronchoconstriction. While epinephrine is the first-line treatment for its vasopressorand bronchodilatory effects, refractory respiratory distress requires secondary interventions to stabilize the airway. Targeted beta-2 agonists are used to provide localized relief of bronchospasm.

Rationale:

A.Selegiline is a monoamine oxidase inhibitor (MAOI) used primarily in the management of Parkinson's disease. It has no role in the acute treatment of anaphylaxis or respiratory distress. Administering an MAOI in an emergency setting could actually lead to dangerous drug interactions with the epinephrine already given, potentially triggering a hypertensive crisis or cardiac arrhythmia.

B.Abatacept is a selective costimulation modulator used for the treatment of rheumatoid arthritis by inhibiting T-cell activation. It is a maintenance medication for chronic autoimmune conditions and does not provide the rapid bronchodilation required for an acute allergic emergency. Its onset of action is far too slow to address the immediate threat of airway occlusion following a bee sting.

C.Sucralfate is a gastroprotective agent that forms a complex over ulcer sites in the stomach. It is administered orally and has no systemic effect on the respiratory or cardiovascular systems. Using sucralfate in a client with severe dyspnea is inappropriate and dangerous, as the patient is at high risk for aspiration and requires immediate parenteral or inhaled interventions.

D.Albuterol is a rapid-acting beta-2 adrenergic agonist that provides direct bronchodilation to relieve the wheezing and airway constriction associated with anaphylaxis. When a client has a suboptimal response to epinephrine, inhaled albuterol helps to further relax the smooth muscles of the bronchioles. This is a critical secondary intervention to improve ventilation and reduce the work of breathing.